GAITHERSBURG, Md., Jan. 14 /PRNewswire/ -- VIRxSYS Corporation, a privately held company developing gene therapies for HIV and genetic diseases, and Lentigen Corporation, a privately-owned biotechnology company focused on the manufacture and development of lentiviral vectors, today announced that they have agreed to settle the pending litigation between the two companies. The parties will dismiss all claims and counterclaims asserted in the lawsuit, which has been pending in the Circuit Court for Baltimore County in Maryland. Additional terms and conditions of the settlement are confidential.
VIRxSYS is a private biotechnology company using proprietary lentiviral vector delivery and RNA payload platforms to develop therapies for serious human diseases. The Company's initial lentiviral delivery technology was exclusively licensed from The Johns Hopkins University and has been substantially advanced in the Company's laboratories. The RNA payload technology was acquired and has been integrated with the Company's lentiviral delivery technology. In addition to preclinical programs for genetic and other serious diseases, the Company is currently developing gene and vaccine therapies for HIV, one of which has advanced to Phase II human clinical trials. More information regarding VIRxSYS can be found at http://www.virxsys.com. Details for the Phase II study can be found at the NIH clinical trials website at clinicaltrials.gov/show/NCT00131560.
About Lentigen Corporation
Lentigen Corporation is a privately-owned biotechnology company focused
on the manufacturing and development of lentiviral vectors using its
proprietary gene delivery technology for a wide range of applications in
biotechnology and medicine. Lentiviral vectors are highly adapted delivery
vehicles that can transport genes or gene silencing sequences into cells
with high efficiency and stability. Lentigen is pos
|SOURCE VIRxSYS Corporation and Lentigen Corporation|
Copyright©2008 PR Newswire.
All rights reserved